Based on the negative results of the phase III, double-blind COSMIC 313 trial, the American Society of Clinical Oncology has updated its rapid recommendations for
In China, a phase III trial of nimotuzumab plus gemcitabine shows significantly improved overall survival (OS) and progression-free survival (PFS) in patients with locally advanced
Two research studies report positive results with the use of the highly selective potent and brain-penetrant RET inhibitor selpercatinib, including first-line treatment of advanced RET fusion–positive non–small-cell
Compared in a phase 3 trial with gemcitabine–cisplatin in patients with untreated unresectable or metastatic urothelial carcinoma, nivolumab plus gemcitabine–cisplatin resulted in significantly better outcomes,
Perioperative durvalumab improved outcomes in patients with resectable non–small-cell lung cancer (NSCLC) in a study of neoadjuvant/adjuvant immunotherapy. The authors write, “Perioperative regimens that combine
Payments from the pharmaceutical industry are associated with oncologists’ prescribing of cancer drugs of questionable benefit, according to a cohort study of fee-for-service Medicare claims.
At a 1,000-bed teaching hospital in France, drug-related problems (DRPs) occurred less frequently in older patients with cancer cared for using the RECAP (phaRmaceutical care
Compared with leuprolide therapy alone, enzalutamide plus leuprolide improved metastasis-free survival in patients with prostate cancer with high-risk biochemical recurrence, a study shows. “Enzalutamide monotherapy
In the phase 3 CARES-310 trial, 543 patients with unresectable hepatocellular carcinoma had a significant and clinically meaningful improvement in progression-free survival and overall survival
Recurrence-free survival was not improved by adjuvant everolimus therapy in patients with renal cell carcinoma at high risk of recurrence after nephrectomy, according to the